Barclays analyst Balaji Prasad lowered the firm’s price target on Organon to $25 from $28 and keeps an Overweight rating on the shares. Post the 15% fall on the Q3 miss, the firm believes Organon’s valuations have troughed. The analyst says the Microspherix settlement was better than expectations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OGN:
- Ex-Dividend Date Nearing for These 10 Stocks – Week of November 6-10, 2023
- Goldman downgrades Organon to Neutral on ‘agglomeration of issues’
- Organon downgraded to Neutral from Buy at Goldman Sachs
- Organon reports Q3 EPS 87c, consensus $1.07
- ObsEva: Xoma will be receiving full worldwide rights on ebopiprant